CliniLink

📍 Manchester CVRM Masterclass | 20 June 2026

Cardiovascular, Renal & Metabolism — free CPD for UK primary care.

Geoff is 68, T2DM, getting breathless. His old echo read "preserved EF" but nobody ever coded HFpEF. Three NICE guidelines say he should be on an SGLT2 inhibitor right now — but only if the diagnosis is on the record.

If you run annual reviews, code QOF, do structured medication reviews, or just want to feel confident with the overlap of HF, CKD and T2DM — this is your Saturday. Senior speakers, real cases, lunch and refreshments included.

👇 Register: https://clinilink.co.uk/upcoming-events/

📍 Durham CVRM Masterclass | 26 June 2026

From Evidence to Implementation — free CPD for UK primary care.

Real case: Margaret, 62. eGFR 52, ACR 7.4, T2DM, BP 144/88. Three separate NICE guidelines (NG28, NG203, NG181) say she should be on an SGLT2 inhibitor and have her BP optimised. The system said "annual review - all in target."

Spend the day with senior speakers walking through structured CVRM annual reviews, escalation, coding and the conversations that change outcomes. Lunch and refreshments provided.

👇 Register: https://clinilink.co.uk/upcoming-events/

📍 London Deep Dive | 30 May 2026

Standard of Care in Type 2 Diabetes Management — free, NICE-aligned CPD for UK primary care.

David is 56. He has T2DM and a recent NSTEMI. NICE NG28 (2022 update) says: offer an SGLT2 inhibitor with proven CV benefit alongside metformin in established atherosclerotic CVD — regardless of HbA1c. In real life, that step gets missed week after week.

If you do diabetes annual reviews, code QOF, run a structured medication review, or just want to be confident with the "what next after metformin?" question — this Saturday is for you. Senior speakers, real cases, lunch included.

👇 Register: https://clinilink.co.uk/upcoming-events/

A question for primary care colleagues.

A 50-year-old taxi driver with established cardiovascular disease. HbA1c 50 on metformin and an SGLT2 inhibitor. Everything at target.

Do you do anything more?

NG28 says yes. Add the GLP-1 receptor agonist. Cardiovascular protection is now irrespective of HbA1c.

Six things like this in our London Deep Dive on Saturday 30 May. Standard of Care in Type 2 Diabetes Management. Royal Nawaab Perivale.

Lunch, refreshments and CPD certificate included.

Register: clinilink.co.uk/upcoming-events

Tag a colleague who would find this useful.

📍 Manchester Deep Dive | 16 May 2026

Managing Allergy & Women's Health — free CPD for UK primary care HCPs.

Case study from clinic: Sarah, 38. Cycled through OTC antihistamines for 6 months. Sleep poor, periods now heavy. The "hay fever" review was actually two open NICE pathways — allergic rhinitis (INCS first-line per NICE CKS) AND peri-menopause / HMB (NG23, NG126).

Come spend a Saturday with us, your peers and senior speakers walking through cases just like this with structured, NICE-aligned escalation. Lunch and refreshments included.

👇 Register: https://clinilink.co.uk/upcoming-events/

Come join us at CPC London we are exhibiting at Stand B15 also find our CEO speaking on a panel on how to ‘Supporting next generation prescribers”

The Clinical Pharmacy Congress

A question for primary care colleagues.
If you have a patient on a GLP-1 receptor agonist who also takes oral HRT, should you do anything differently?

Most clinicians answer "no". The current BMS guidance says "yes".

Six prescribing pearls like this one in our Manchester Deep Dive on Saturday 16 May. Allergy and Women's Health, both covered. Lunch, refreshments and CPD certificate included.

Full agenda and registration: clinilink.co.uk/upcoming-events

Tag a colleague who would find this useful

🎉 It’s happening TODAY in Leeds!

Our Deep Dive: Cardio-Renal-Metabolic Disease is underway right now at The Queens Hotel, City Square, Leeds — and what an incredible day it’s shaping up to be.

We’re so proud to bring together dedicated primary care professionals for a full day of expert-led, CPD-accredited learning — completely free to attend.

A huge thank you to our brilliant faculty:
🎤 Hannah Beba — Consultant Pharmacist, West Yorkshire & Leeds Health and Care Partnership
🎤 Dr Waqas Tahir — GPwER in Diabetes & Cardiometabolic Medicine

Today’s sessions are covering some of the most pressing topics in primary care right now — from CKD and lipid management to diabetes and the obesity epidemic. The conversations in the room have been fantastic.

This is exactly why we do what we do at CliniLink — bringing clinicians together to learn, connect, and take better care of their patients.

Stay tuned for highlights from the day! 💙

💊 | Pregabalin & Renal Function

Quick safety reminder for clinicians 👇

Pregabalin is almost entirely renally excreted — so dosing should always reflect creatinine clearance (CrCl).

In patients with CKD, inappropriate dosing can increase the risk of:
• Dizziness
• Sedation
• Falls
• Confusion

In busy primary care, it’s easy to default to 75 mg BD.
But a quick CrCl calculation can make a big difference to patient safety.

Small adjustment. Big impact.

Are you routinely checking CrCl before titrating?